Prevalence and demography of resistance
| CPE | MRSA | VRE | ESBL |
Colonised
≥1 bacteria* | ||||||
| n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | |
| National (n=5117) | 4 (0.1%) | 0.0% to 0.2% | 16 (0.3%) | 0.2% to 0.5% | 21 (0.4%) | 0.3% to 0.6% | 230 (4.5%) | 3.9% to 5.1% | 266 (5.2%) | 4.6% to 5.8% |
| Type of area | ||||||||||
| University hospitals (n=2203) | 4 (0.2%) | 0.0% to 0.5% | 6 (0.3%) | 0.1% to 0.6% | 9 (0.4%) | 0.2% to 0.8% | 101 (4.5%) | 3.7% to 5.5% | 116 (5.3%) | 4.4% to 6.3% |
| Regional hospitals (n=2914) | 0 (0%) | 0% to 0.1% | 10 (0.3%) | 0.2% to 0.6% | 12 (0.4%) | 0.2% to 0.7% | 129 (4.4%) | 3.7% to 5.2% | 150 (5.1%) | 4.3% to 6.0% |
| Region | ||||||||||
| North Denmark (n=1055) | 1 (0.1%) | 0.0% to 0.5% | 0 (0%) | 0% to 0.3% | 2 (0.2%) | 0.0% to 0.7% | 39 (3.7%) | 2.6% to 5.0% | 41 (3.9%) | 2.8% to 5.2% |
| Central Denmark (n=1376) | 0 (0%) | 0% to 0.2% | 12 (0.9%) | 0.5% to 1.5% | 10 (0.7%) | 0.3% to 1.3% | 71 (5.2%) | 4.1% to 6.5% | 91 (6.6%) | 5.4% to 8.1% |
| Southern Denmark (n=1195) | 0 (0%) | 0% to 0.3% | 3 (0.3%) | 0.01% to 0.7% | 3 (0.3%) | 0.1% to 0.7% | 57 (4.8%) | 3.6% to 6.1% | 62 (5.2%) | 4.0% to 6.6% |
| Zealand (n=1491) | 3 (0.2%) | 0.0% to 0.6% | 1 (0.1%) | 0.0% to 0.4% | 6 (0.4%) | 0.1% to 0.9% | 63 (4.2%) | 3.3% to 5.4% | 72 (4.8%) | 3.8% to 6.0% |
| Sex | ||||||||||
| Female (n=2558) | 0 (0%) | 0% to 0.01% | 8 (0.3%) | 0.1% to 0.6% | 11 (0.4%) | 0.2% to 0.8% | 108 (4.2%) | 3.5% to 5.1% | 125 (4.9%) | 4.0% to 5.8% |
| Male (n=2529) | 4 (0.2%) | 0.0% to 0.4% | 8 (0.3%) | 0.1% to 0.6% | 10 (0.4%) | 0.2% to 0.7% | 119 (4.7%) | 3.9% to 5.6% | 138 (5.5%) | 4.6% to 6.4% |
| Age (years) | ||||||||||
| 18–49 (n=966) | 0 (0%) | 0% to 0.4% | 2 (0.2%) | 0.0% to 0.7% | 0 (0%) | 0% to 0.4% | 45 (4.7%) | 3.4% to 6.2% | 47 (4.9%) | 3.4% to 6.4% |
| 50–64 (n=1207) | 1 (0.1%) | 0.0% to 0.5% | 4 (0.3%) | 0.1% to 0.8% | 2 (0.2%) | 0.0% to 0.6% | 65 (5.4%) | 4.2% to 6.8% | 70 (5.8%) | 4.5% to 7.3% |
| 65–79 (n=1903) | 1 (0.1%) | 0.0% to 0.3% | 7 (0.4%) | 0.1% to 0.7% | 10 (0.5%) | 0.3% to 1.0% | 86 (4.5%) | 3.6% to 5.6% | 104 (5.5%) | 4.5% to 6.6% |
| >80 (n=1041) | 2 (0.2%) | 0.0% to 0.7% | 3 (0.3%) | 0.1% to 0.8% | 9 (0.9%) | 0.4% to 1.6% | 34 (3.3%) | 2.3% to 4.5% | 45 (4.3%) | 3.2% to 5.7% |
*Five patients had >1 MRB, not included in the numbers.
CPE, carbapenemase-producing enterobacteria; ESBL, extended-spectrum beta-lactamase-producing enterobacteria; MRB, multiresistant bacteria; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci.